LOAD MORE
You're viewed 18 of 25 products
Aripiprazole
References
FAQ's
References
- Oshiro, Yasuo; Sato, Seiji; Kurahashi, Nobuyuki, Carbostyril derivatives, EP367141B1, Jan 10, 1996, Otsuka Pharmaceutical Co., Ltd., Japan (https://patents.google.com/patent/EP0367141B1/en)
- Kubo, Masanori; Mizooku, Yasuo; Hirao, Yukihiro; Osumi, Takahiko, Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 822, Issue: 1-2, Pages: 294-299, 2005 DOI: (10.1016/j.jchromb.2005.06.023)
Frequently Asked Questions
2.What are some of the known Aripiprazole impurities found in the drug substance?
1-(2,3-dichlorophenyl)-piperazine hydrochloride, (7-(4-chlorobutoxy-3,4-dihydroquinolin-2(1H)-one), (8-(2,3-dichlorophenyl)-8-aza-5-azoniaspiro[4,5]decano bromide, (7-hydroxy3,4-dihydroquinolin-2(1H)-one) are some of the known Aripiprazole impurities found in the drug substance.
3.How are the Aripiprazole impurities formed?
Aripiprazole impurities form from unreacted starting materials, by-products, intermediates, reagents, and degradation.
4.How do we identify degradation impurities in Aripiprazole?
The liquid chromatography-mass spectrometry (LC-MS) method can identify major degradation impurities in Aripiprazole.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.